RT Journal Article
T1 Prevalence of non-alcoholic fatty liver disease (NAFLD) in a cohort of patients with type 2 diabetes: the PHIGNA-DM2 study.
T2 Prevalencia de la hepatopatía grasa no alcohólica (HGNA) en una cohorte de pacientes con diabetes de tipo 2: el estudio PHIGNA-DM2.
A1 Martínez-Ortega, Antonio Jesús
A1 Piñar Gutiérrez, Ana
A1 Lara-Romero, Carmen
A1 Remón Ruiz, Pablo Jesús
A1 Ampuero-Herrojo, Javier
A1 de Lara-Rodríguez, Irene
A1 Romero-Gómez, Manuel
A1 García Luna, Pedro P
A1 Soto-Moreno, Alfonso
K1 Diabetes de tipo 2. Diabetes mellitus. Enfermedad de hígado graso no alcohólico. Fibrosis hepática. Esteatosis hepática. Elastografía.
AB Background: type 2 diabetes (T2D) is a risk factor for nonalcoholic fatty liver disease (NAFLD). Objective: to evaluate the prevalence of NAFLD in a cohort of patients with T2D. Methods: an observational, descriptive study performed between May 2018 and December 2019 at the Endocrinology and Nutrition Unit. The χ² test was performed for qualitative variables and a non-parametric test for the comparison of medians of quantitative variables. Steatosis degree was defined by the coefficient attenuated parameter (CAP): (S0:  288 dB/m) or stiffness: F0-F1:  15 kPa, using transient elastography (TE) (FibroScan®). A univariate analysis was performed and subsequently a multivariate analysis with statistically significant variables used to study the predictive factors of intense steatosis and advanced fibrosis. Results: n = 104 patients with T2D; 84 (80.7 %) were obese. TE demonstrated advanced fibrosis in 20 % and intense steatosis (S3) in more than 50 %. Lower total bilirubin (OR: 0.028; 95 % CI: (0.002-0.337); p = 0.005) was found to be an independent factor for S3 steatosis in the multivariate analysis. BMI ((OR: 1.497; 95 % CI: (1.102-2.034); p = 0.01)) was a predictive factor for advanced fibrosis in a multivariate analysis. Conclusions: NAFLD-associated intense steatosis and NAFLD-associated fibrosis were commonly found in patients with T2DM and obesity. Diabetic patients should be screened for liver disease as one more target organ.
YR 2022
FD 2022
LK http://hdl.handle.net/10668/21761
UL http://hdl.handle.net/10668/21761
LA en
DS RISalud
RD Apr 19, 2025